Weihe Zhang

发表

Small Molecule Inhibition of MERTK Is Efficacious in Non–Small Cell Lung Cancer Models Independent of Driver Oncogene Status

S. Frye, B. Hendriks, P. Harari, 2015, Molecular Cancer Therapeutics.

Superstable magnetic nanoreactors with high efficiency for Suzuki-coupling reactions.

Xuecheng Chen, E. Mijowska, Weihe Zhang, 2014, Nanoscale.

MERTK receptor tyrosine kinase is a therapeutic target in melanoma.

C. Miller, S. Frye, A. Tan, 2013, The Journal of clinical investigation.

Discovery of Macrocyclic Pyrimidines as MerTK‐Specific Inhibitors

S. Frye, M. Machius, M. Miley, 2017, ChemMedChem.

Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia

S. Frye, H. Earp, A. Hill, 2015, Oncotarget.

UNC1062, a new and potent Mer inhibitor.

S. Frye, W. Janzen, H. Earp, 2013, European journal of medicinal chemistry.

Discovery of Mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis.

S. Frye, W. Janzen, M. Machius, 2013, Journal of medicinal chemistry.

UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models

Kristen M. Jacobsen, S. Frye, J. Tyner, 2016, Clinical Cancer Research.

The MERTK / FLT 3 inhibitor MRX-2843 overcomes resistance-conferring FLT 3 mutations in acute myeloid leukemia

S. Frye, C. Jordan, Catherine C. Smith, 2018 .

The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia.

S. Frye, H. Earp, C. Jordan, 2016, JCI insight.

Highly Selective MERTK Inhibitors Achieved by a Single Methyl Group.

S. Frye, D. Drewry, Yuewei Zhang, 2018, Journal of medicinal chemistry.

Efficient solution-phase synthesis of 4,5,7-trisubstituted pyrrolo[3,2-d]pyrimidines.

Jing Liu, Weihe Zhang, Xiaodong Wang, 2013, ACS combinatorial science.

UNC2025, a Potent and Orally Bioavailable MER/FLT3 Dual Inhibitor

D. Newton, S. Frye, W. Janzen, 2014, Journal of medicinal chemistry.

Kinome profiling of non-Hodgkin lymphoma identifies Tyro3 as a therapeutic target in primary effusion lymphoma

S. Frye, Carolina P. Lin, H. Earp, 2019, Proceedings of the National Academy of Sciences.

UNC5293, a potent, orally available and highly MERTK-selective inhibitor.

S. Frye, Xiaodong Wang, H. Earp, 2021, European journal of medicinal chemistry.

Pseudo-cyclization through intramolecular hydrogen bond enables discovery of pyridine substituted pyrimidines as new Mer kinase inhibitors.

S. Frye, W. Janzen, M. Machius, 2013, Journal of medicinal chemistry.

Abstract 1736: A novel Mer tyrosine kinase inhibitor mediates increased cell killing in combination with FGFR inhibition

S. Frye, T. P. Newton, H. Earp, 2014 .

Discovery and Optimization of 2H-1λ2-Pyridin-2-one Inhibitors of Mutant Isocitrate Dehydrogenase 1 for the Treatment of Cancer.

Mindy I. Davis, D. Urban, Adam Yasgar, 2021, Journal of medicinal chemistry.

Design and Synthesis of Novel Macrocyclic Mer Tyrosine Kinase Inhibitors.

S. Frye, M. Machius, M. Miley, 2016, ACS medicinal chemistry letters.

Abstract 947: A small molecule Mer tyrosine kinase inhibitor (UNC MerTKi) effectively inhibits growth of murine melanoma

David B. Darr, N. Sharpless, S. Frye, 2014 .

Abstract 1740: Development of a novel small molecule MER tyrosine kinase inhibitor with therapeutic activity in cell culture and mouse models of acute lymphoblastic leukemia

S. Frye, W. Janzen, H. Earp, 2014 .

MERTK receptor tyrosine kinase is a therapeutic target in melanoma.

C. Miller, S. Frye, J. M. Shields, 2013, The Journal of clinical investigation.

The small‐molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis

S. Frye, X. Wang, H. Earp, 2018, Journal of thrombosis and haemostasis : JTH.

Discovery of Mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis.

S. Frye, M. Machius, M. Miley, 2013, Journal of medicinal chemistry.

Discovery of Macrocyclic Pyrimidines as MerTK‐Specific Inhibitors

S. Frye, M. Machius, M. Miley, 2017, ChemMedChem.